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Abstract
This study investigated the validity and reliability of fixed strain gauge measurements of isometric quadriceps force
in patients with chronic obstructive pulmonary disease (COPD). A total cohort of 138 patients with COPDwere
assessed. To determine validity, maximal volitional quadriceps force was evaluated during isometric maximal
voluntary contraction (MVC) manoeuvre via a fixed strain gauge dynamometer and compared to (a) potentiated
non-volitional quadriceps force obtained via magnetic stimulation of the femoral nerve (twitch (Tw); n¼ 92) and
(b) volitional computerized dynamometry (Biodex; n ¼ 46) and analysed via correlation coefficients. Test–retest
and absolute reliability were determined via calculations of intra-class correlation coefficients (ICCs), smallest
real differences (SRDs) and standard errors of measurement (SEMs). For this, MVC recordings in each device
were performed across two test sessions separated by a period of 7 days (n ¼ 46). Strain gauge measures of
MVC demonstrated very large correlation with Tw and Biodex results (r ¼ 0.86 and 0.88, respectively,
both p < 0.0001). ICC, SEM and SRD were numerically comparable between strain gauge and Biodex devices
(ICC ¼ 0.96 vs. 0.93; SEM ¼ 8.50 vs. 10.54 Nm and SRD ¼ 23.59 vs. 29.22 Nm, respectively). The results
support that strain gauge measures of quadriceps force are valid and reliable in patients with COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is
associated with systemic manifestations and comor-
bidities that impact functional capacity, health-
related quality of life and prognosis.1 Peripheral
muscle weakness, particularly of the large quadri-
ceps muscles, is highly prevalent in patients with
COPD2,3 and is an important target of comprehen-
sive disease management due to its vital role in
activities of daily living, its contribution to exercise
intolerance,4 known dysfunction compared to
healthy controls5–7 and remediable nature.8 Addres-
sing this dysfunction is a key aim of the exercise
training component of pulmonary rehabilitation.3,9
Interestingly, little is known about the psychometric
properties of strength measures in an elderly popu-
lation in general and in patients with COPD in par-
ticular. Since the latter have altered structural and
metabolic properties of their skeletal muscles,6 it
seems important to specifically validate techniques
to assess muscle strength in this population.
Measurement of peripheral muscle force is typi-
cally simple and feasible for most patients with
COPD. Common manoeuvres used to measure voli-
tional muscle force include isometric, isotonic or iso-
dynamic maximum voluntary contractions (MVCs)10
or dynamic one-repetition maximum contraction
(1RM).11 Common equipment used for this purpose
includes handheld dynamometry, seated strain
gauge12 or computerized dynamometry.13 The choice
of technique usually depends upon the desired level of
accuracy and clinical indication(s). All tests suffer
from potential error related to central fatigue, poor
motivation or variability induced by the assessor.
Non-volitional assessment of muscle force is per-
formed via electrical or magnetic stimulation of a
peripheral motor nerve to derive a measure of muscle
twitch (Tw) force. While excellent correlations have
been demonstrated between Tw with MVC force in
healthy controls14 and patients with COPD,15 such
measures are not routinely performed in clinical prac-
tice due to the high equipment costs and necessity for
examiner skill. They remain, however, a reference
method in research settings to answer specific physio-
logic questions.
In patients with COPD, quadriceps MVC man-
oeuvres are frequently performed via isometric con-
traction.16 Isometric MVCs consist of maximal
contractions conducted against a resistance at a fixed
joint angle.7 They are easily implemented into clinical
practice and provide reliable and reproducible mea-
sures of muscle force.6 Measurement of isometric
quadriceps force is often performed via commercially
available computerized dynamometers; however,
despite its reputation as a ‘reference method’18 for
volitional muscle force testing, its use in clinical prac-
tice is impeded by the high equipment costs and large
space requirements. The fixed strain gauge offers sim-
ple and fast user applicability at considerably lower
cost than computerized dynamometry and was recom-
mended as a ‘low implementation cost’ technique to
measure isometric force in the recent american thor-
acic society (ATS)/european respiratory society
(ERS) statement on limb muscle dysfunction in
COPD.6 A review by Robles and colleagues16 high-
lighted its increasing use in COPD research but cited a
lack of COPD-specific reliability data as an important
area for future research. This knowledge gap under-
pins the relevance of the present research.
The primary aim of this study was therefore to
determine the validity (how well an instrument mea-
sures what it purports to measure),19 test–retest relia-
bility (the magnitude of the error in observed
measurements of the inherent variability between sub-
jects)20 and agreement (how close two measurements
from the same subject are)20 of fixed strain gauge
measures of quadriceps muscle force in patients with
COPD. The secondary aims were to determine the
presence of (1) test fatigue (defined by a decreased
repeated force measurement during a single visit),
(2) a learning effect (defined by an increased muscle
force measurement during the second visit compared
to the first visit, with 7 days in between), and (3) any
true absolute difference between quadriceps force
measurements obtained from the strain gauge and
Biodex devices across both visits.
Methods
Test procedures
Data from a sample of convenience of 138
individuals participating in the previous21–23 or cur-
rent (NCT02113748) clinical trials at UZ Gasthuis-
berg, Leuven (Belgium) were included in this
combined retrospective/prospective study. All studies
were approved by the ethics committee of University
Hospital Leuven, and a written informed consent was
obtained from all patients in accordance with the
Declaration of Helsinki. Inclusion criteria comprised
diagnosis of COPD according to global initiative for
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chronic obstructive lung disease (GOLD) recommen-
dations,1 age 40 years and smoking history
10 pack-years. Patients were ineligible for inclusion
if they had a primary respiratory disease other than
COPD (e.g. asthma) documented in their medical
record, impairment of normal biomechanical move-
ment (e.g. significant coexisting orthopaedic, neuro-
logical or other condition) or significant cognitive
impairment, as judged by study investigators.
In one cohort of 92 patients, peak volitional contrac-
tile quadriceps force was assessed during an isometric
MVCmanoeuvre via a fixed strain gauge dynamometer
with signal analogue force transducer (546QD; CDS
Milan, Italy) and amplifier (Biopac MP150; Biopac
Systems, Goleta, California, USA). Peak volitional
force was compared with non-volitional Tw force
obtained via magnetic stimulation of the femoral nerve
at 100% power output of a Magstim stimulator (Mag-
stimCoLtd,Whitland,UK)3 secondspost-MVC(in the
passive, relaxed state).Maximality of the non-volitional
contractionwas ensured by increasing the power output
of the magnetic stimulator and ensuring that the Tw
force did not further increase between 90% and 100%
of the power output (supramaximal stimulation). These
measurements were performed during a single visit,
with patients seated in a semi-reclined chair that pro-
vided 90 knee flexion and 120 hip flexion to optimize
the stimulation of the femoral nerve, in accordance
with previously published data.21 Isometric quadri-
cepsMVCswere sustained for 3 seconds and repeated
a total of five times, with 30-second rest intervals
between contractions. These data were retrospec-
tively collected from patients’ records in the afore-
mentioned studies.
An independent, second cohort of 46 patients was
prospectively assigned to undergo repeated assessments
conducted over two visits, separated by 1 week. In this
group, measures of peak isometric quadriceps force and
torque were obtained from both the fixed strain gauge
and a computerized dynamometer (Biodex system4 pro
–EnrafNonius;Delft, theNetherlands)with aminimum
of 30 minutes rest between test procedures. Device
sequence (strain gauge/Biodex or Biodex/strain gauge)
was determinedvia randomallocation andkept constant
across visits (Figure 1).
While measures of peak isometric quadriceps force
were yielded from both methods, slight differences
existed between the test procedures. In accordance
with conventional procedures, MVCs for the Biodex
were performed over four manoeuvres of 6 seconds
duration with 20-second rest intervals and a knee posi-
tion of 60 flexion. Quadriceps force expressed as
absolute and percentage of predicted normal values.24
Strain gauge measures were obtained over five MVC
manoeuvres of 5 seconds duration with 30-second rest
intervals. As this cohort did not need to perform non-
volitional (Magstim) procedures, both the hip and knee
joints were positioned in 90 flexion (conventional test
position for strain gauge). In order to compare data
between the strain gauge (expressed as force, in New-
tons) and Biodex (expressed as torque, Newton metres
[Nm]) in this cohort, leg length was measured from the
middle of the fibula head (axis of rotation) to the top of
malleolus (fixed point where the force was applied)
and strain gauge torque measures calculated using the
formula (Nm ¼ leg length [m]  Newtons).
All data measurements were recorded after one
practice trial on each device, and all patients received
maximal encouragement by the investigator during
MVCmanoeuvres, including provision of visual feed-
back on a computer screen. Final test results were not
disclosed to patients until completion of the last test
procedure. All test procedures were conducted by the
same assessor for each patient, and the assessment
was standardized to the right leg. The highest (peak)
value of three reproducible manoeuvres from five
attempts (allowing no more than 5% variance) was
used for analysis.
All participants underwent detailed lung function
and functional exercise capacity (6-minute walk test)
assessments according to ERS standards25,26 for pur-
poses of characterization.
Figure 1. Overview of data collection design for validity and reliability study (n ¼ 46).
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Analysis
Statistical analyses were performed with SAS 9.4
(SAS Institute Inc., Cary, North Carolina, USA).
Data are presented as mean + SD. Statistical sig-
nificance was denoted by p < 0.05 for all statistical
tests.
Validity was investigated via two methods: inspec-
tion of the relationship between peak volitional strain
gauge quadriceps force (Newton [N]) and Tw (N), in
the cohort of 92 patients, and Biodex measures (Nm),
in the cohort of 46 patients. Pearson correlation coef-
ficients were calculated, with r values in the range of
0.0–0.1 considered trivial, 0.1–0.3 small, 0.3–0.5
moderate, 0.5–0.7 large, 0.7–0.9 very large and
0.9–1.0 extremely large.27
Strain gauge and Biodex test–retest reliability
(n ¼ 46) across the two clinical visits were deter-
mined via calculation of intra-class correlation coef-
ficients (ICCs) using the formula ICC ¼ S2B/(S2B þ
S2W), where S
2
B and S
2
W represent the between-
subject variance (S2B) and the within-subject variance
(S2W). ICC values were interpreted as <0.4 poor,
0.4–0.75 fair to good and >0.75 excellent.28 Absolute
reliability was evaluated by the standard error of mea-
surement (SEM), calculated as SEM ¼ Sx p
(1ICC), where Sx is the standard deviation of the
baseline measurement. The smallest real difference
(SRD), indicating a 95% confidence interval around
the SEM measurement, was calculated from the for-
mula SRD ¼ 1.96  p2  SEM.29 The percentage
was calculated as SRD% ¼ (SRD/mean)  100.
Test–retest agreement of volitional torque mea-
sures for both devices during the two clinic visits
(n ¼ 46) was also investigated via Bland–Altman
plots (mean difference vs. average of the two visits)
for each device (separately) using GraphPad Prism
5.0 and mean difference and limits of agreement
reported. Repeatability was reported via the coeffi-
cient of repeatability and its precision, as described
by Bland et al.30
The secondary aims (n ¼ 46) were addressed via
linear mixed models with quadriceps torque as the
dependent variable. Class variables were order of
measurement (first or second assessment, indicative
of ‘fatigue’), visit (first or second, indicative of ‘learn-
ing’), device (strain gauge or Biodex, indicative of
absolute difference between both devices) and patient
identification. An interaction factor (device  visit)
was included to investigate any differences in learn-
ing effects attributable to device.
Results
Baseline characteristics of both cohorts from the
study are presented in Table 1. One patient from the
first cohort and three from the second did not perform
the 6-minute walk test (6MWT). In two patients, one
force measurement on one of the devices was missing,
so these data were not included in the test–retest anal-
yses, resulting in n ¼ 45 and n ¼ 44 for strain gauge
and Biodex, respectively.
Validity
A very large correlation was evident between strain
gauge measures of peak quadriceps force and non-
volitional Tw force (r ¼ 0.86, p < 0.001; Figure 2),
independent of gender (n ¼ 92). In the cohort of
46 patients, a very large correlation was also evident
between MVC recorded from strain gauge (torque
calculated from the original force measures) and
MVC from Biodex (r¼ 0.88, p < 0.0001), as assessed
during the first visit.
Test–retest and absolute reliability
A summary of peak volitional quadriceps force mea-
sures and reliability estimates (ICC, SEM, SRD,
SRD%) obtained during the two visits for both
devices is presented in Table 2.
Table 1. Participants’ characteristics.a
Validity
cohort
Validity and
reliability cohort
n 92 46
Gender (%men) 67 78
Age (years) 65+ 8 67+ 6
BMI (kg/m2) 25+ 6 26+ 4
FEV1/FVC 0.41 + 0.12 0.50 + 0.14
FEV1 (%pred) 45+ 15 65+ 21
6MWT (m) 426+ 129 515+ 136
6MWT (%pred) 66+ 19 81+ 19
Quadriceps force (%pred)b 80+ 35 89+ 20
BMI: body mass index; FEV1: forced expiratory volume in 1 sec-
ond; FVC: forced vital capacity; 6MWT: 6-minute walk test.
aData are presented as mean + SD. One patient from the first
cohort and three from the second did not perform 6MWT. One
patient from the second cohort did not perform muscle force
assessment during visit 1 due to leg pain after completion of the
6MWT.
bPercentage of predicted was calculated for quadriceps force
measured by Biodex.
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Test–retest Bland–Altman analyses for strain
gauge (Figure 3) and Biodex (Figure 4) revealed good
mean agreement and narrow limits of agreement
across the two visits. For the strain gauge, mean dif-
ference was 3.74 Nm and limits of agreement17.68
Nm to 25.15 Nm. For Biodex, mean difference was
1.67 Nm and limits of agreement 31.74 Nm to
28.41 Nm. The coefficients of repeatability were
+21.42 and +30.07 Nm for strain gauge and Bio-
dex, respectively.
Further explorations of test performance
(secondary study aims)
Mean muscle force significantly decreased (6%)
from the first to second test of each visit
(136 + 40 Nm vs. 128 + 40 Nm, respectively;
p < 0.001). No differences existed between mean
muscle force measurements at visits 1 and 2 (132 +
40 Nm vs. 133 + 40 Nm, respectively; p ¼ 0.53),
and no learning effects were detected for either
device (interaction device  visit, p ¼ 0.18). Overall
mean muscle force measures did not differ between
strain gauge and Biodex (133 + 40 Nm and 132 +
40 Nm, respectively; p ¼ 0.64).
Discussion
The present study findings are novel and relevant in
supporting the validity of the strain gauge to measure
MVCs in patients with COPD. It also indicates that
measurements obtained with this device are at least as
reliable and reproducible as those obtained via com-
puterized dynamometry, considered the ‘gold stan-
dard’ for MVC measures.18 As such, these data
strongly support the recommendations of the ATS/
ERS regarding assessment of quadriceps force using
Figure 3. Bland–Altman plot of test–retest agreement
across visits 1 and 2, strain gauge (n ¼ 44).
Figure 4. Bland–Altman plot of test–retest agreement
across visits 1 and 2, Biodex (n ¼ 45).
Figure 2.Correlation between non-volitional and maximal
voluntary quadriceps force measured by the strain gauge
(n ¼ 92).
Table 2. Quadriceps force and reliability estimates
obtained from visits 1 and 2 for strain gauge and Biodex
(based on the cohort of 46 patients).
Strain gauge Biodex
Quadriceps torque V1,
Nm (mean + SD)
130.82+ 42.48 132.54 + 39.83
Quadriceps torque V2,
Nm (mean + SD)
135.30+ 42.87 130.92 + 40.78
ICC 0.96 0.93
SEM, Nm 8.50 10.54
SRD, Nm 23.56 29.22
SRD, % 18.01 22.05
V1: first visit for measurements; Nm: Newton meter; V2: second
visit for measurements; ICC: intra-class correlation coefficient;
SEM: standard error of measurement; SRD: smallest real differ-
ence; %: percentage.
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the strain gauge in patients with COPD.6 This is
important because robust computerized dynam-
ometers, while commonly used to assess isometric
force in COPD research,17,31 are not easily available
within the clinical environment. A recent interna-
tional survey reported the evaluation of lower limb
muscle force, upper limb force, lung function and
body composition (pooled response option), occurs
in only 20% of pulmonary rehabilitation programs,32
potentially due to limitations such as the availability
of appropriate equipment. Our findings add to this
scant literature to support the use of a strain gauge
as a simple but equally robust measure of quadriceps
muscle force in patients with COPD.
A strength of the present study was validation of
the strain gauge against both volitional and non-voli-
tional quadriceps contractions. The very large rela-
tions between these measures in our data
(p < 0.0001, r2¼ 0.76) are in line with those observed
by Polkey et al.14 who reported on the use of magnetic
femoral nerve stimulation in healthy subjects and
those with suspected muscle weakness (p < 0.0001,
r2 ¼ 0.83). Validation of the strain gauge against the
Biodex system enabled comparison with gold stan-
dard dynamometry for assessment of muscle function.
The very large correlation between isometric MVC
measures from the strain gauge and Biodex reinforces
the validity of this technique.
To the best of our knowledge, test–retest reliability
of the fixed strain gauge has not been previously
reported, nor has direct comparison been made
between the Biodex system 4 pro used in isometric
mode. Test–retest reliability of the strain gauge was
confirmed in our study through the verified ICC, SEM
and SRD estimates. The results slightly favoured the
strain gauge over Biodex (lower SEM and SRD val-
ues); however, the very small magnitude of difference
is of questionable clinical relevance. These outcomes
demonstrate high precision of the measurement29 to
discriminate small differences upon measurement.33
No pattern of systematic over- or underestimation was
observed for the strain gauge in the Bland–Altman
plot and dispersion around the mean was less than the
Biodex. Taken in consideration with the small mean
differences of each device (3.74 and 1.67 Nm for
strain gauge and Biodex, respectively) and the accep-
table repeatability coefficients (+ 21.42 for strain
gauge and+ 30.07 for Biodex), we feel this supports
the strain gauge as an adequate method for assessing
quadriceps force compared to Biodex. Our test–retest
reliability estimates for the Biodex system compare
favourably with those of other studies performed in
patients with COPD,34 healthy subjects35,36 and peo-
ple with late effects of polio,37 strengthening the
external validity of our findings. While the SRD for
both devices was relatively large in our study, this
appears consistent with the findings from Flansbjer
and Lexell37 derived from Biodex measures of iso-
metric extension of knee extension (SRD% ¼ 17.8
in the less affected limb).
We described slight differences in the testing pro-
tocols between the two devices across the different
patient cohorts, attributed primarily to positioning of
the hip and knee joints. The increased hip extension
with the strain gauge was necessary in order to pro-
vide effective femoral nerve stimulation with the
magnetic stimulator, and the decreased knee flexion
with the Biodex used in accordance with previous
research in the COPD patient group that allows the
comparison with predicted values.24 Position varia-
tion may have influenced the generation of torque due
to changes in neural activation, muscle fibres length–
tension relationship (with 60 typically considered
‘ideal’), and/or the complex force transmission
through the knee joint.38,39 Early data from Knapik
et al.40 indicated that isometric peak torque of the leg
extensors was greater at 60 than 90 flexion, and
Hahn41 more recently verified that the isometric
multi-joint leg extension torque-generating capacity
also differs according to knee angle in young healthy
men. Data from Krishnan and Williams39 and Herzog
et al.,42 however, contradict this, showing an absence
of difference in isometric torque generated at either
60 or 90 knee flexion. In consideration of this infor-
mation, and the very comparable data pertaining to
absolute force and ICCs from both devices in present
study, we do not suspect knee position to have
adversely affected the findings of our data. Interest-
ingly, the detection of fatigue in our sample suggests
that 30 minutes may not be enough for complete
muscle recovery. This fact did not, however, prevent
clear analysis of results regarding the validity and
reliability of the strain gauge as the randomized
device order enabled device-specific analysis to pro-
ceed with confidence.
Future research may be indicated to develop pre-
dictive normal values for strain gauge measures of
quadriceps strength. Early research in this area43 sug-
gests normal values for adults’ MVC are approxi-
mately 75% of the body weight. While body weight
is an important factor, a minimum age and gender
should also be taken into account. These aspects were
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considered in the prediction formula later described
by Seymour et al.44 However, the need for fat-free
mass measurement limits its applicability in clinical
practice. An updated, robust but simple estimate
would be of importance to the future clinical imple-
mentation of this technique – an integral outcome of
the present research.
In summary, this study provides evidence that the
fixed strain gauge method to measure quadriceps
muscle strength, as proposed in the consensus state-
ment of the ATS and ERS,6 is valid and reliable for
the measurement of isometric quadriceps force in
patients with COPD.
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